EGFR and non-small cell lung carcinoma: Indeed, FGFR inhibition in drug-tolerant EGFR-mutant non-small cell lung cancer (NSCLC) cells, harboring EGFR T790 M, effectively synergized with EGFR inhibitors and overcame EMT-mediated acquired drug resistance, thereby providing a rationale for combined FGFR and EGFR inhibition for EGFR-mutated cancer cells [174].